Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor a (FRa)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.
Mirvetuximab Soravtansine
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor a (FRa)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials. ### Output: Mirvetuximab Soravtansine